Dr. Gillard is President of the biotechnology consulting firm, BioGill Consultants Inc. He brings a wealth of experience in drug discovery and development, to the Board of NuChem Therapeutics. An accomplished organic chemist with past experience as Director of Medicinal Chemistry at Merck Research Laboratories; VP Research at Canada’s most successful biotech company, BioChem Pharma, and most recently as founder, CSO and EVP of Aegera Therapeutics Inc. Dr. Gillard directly participated in more than ten clinical development programs, several of which have become major, multi-billion drugs (Singulair(R) Epivir(R) and Lamivudine(R)).
Dr. Gillard held executive management positions, Scientific Advisory Board memberships and Board Directorships of a number of private and public biotechnology companies across Canada. These companies include Stressgen, GlycoDesign and Apoptogen Kinetek and IBEX Technologies. Dr. Gillard has non-profit Board experience as a Director of the Ottawa Life Sciences Council, helping to promote biotech industry in Eastern Ontario.
Dr. Gillard maintains strong academic ties and involvement, he has an extensive publication record and is currently Adj. Professor in the Department of Pharmacology and Therapeutics at McGill University, where he teaches and mentors graduate students. He is also very active in the Canadian University/Granting Council and funding programs field.